Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data

被引：0
|
作者：
Colombel, Jean-Frederic
Lemann, Marc
Allez, Matthieu
Mitchev, Krassimir
Jamoul, Corinne
Hebuterne, Xavier
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A181 / A181
页数：1
相关论文
共 50 条
  • [21] Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
    Colombel, Jean-Frederic
    Sandborn, William J.
    Allez, Matthieu
    Dupas, Jean-Louis
    Dewit, Olivier
    D'Haens, Geert
    Bouhnik, Yoram
    Parker, Gerald
    Pierre-Louis, Bosny
    Hebuterne, Xavier
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (03) : 423 - +
  • [22] Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
    Lichtenstein, Gary R.
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (07) : 600 - 609
  • [23] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease
    Niels Vande Casteele
    Diane R. Mould
    Jason Coarse
    Iram Hasan
    Ann Gils
    Brian Feagan
    William J. Sandborn
    Clinical Pharmacokinetics, 2017, 56 : 1513 - 1523
  • [24] Certolizumab Pegol Demonstrates Efficacy in Maintaining Response and Remission in Patients With Active Crohn's Disease Regardless of Their Immunosuppressant Treatment Status at Entry to the PRECiSE 2 Study
    Schreiber, Stefan
    Khaliq-Kareemi, Munaa
    Lawrance, Ian C.
    Thomsen, Ole O.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [25] Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease
    Vande Casteele, Niels
    Mould, Diane R.
    Coarse, Jason
    Hasan, Iram
    Gils, Ann
    Feagan, Brian
    Sandborn, William J.
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1513 - 1523
  • [26] Efficacy of certolizumab pegol therapy in patients with Crohn's disease.
    Shafran, I
    Al-Maani, S.
    Burgunder, P.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S62 - S62
  • [27] SUCCESSFUL INDUCTION OF CLINICAL RESPONSE AND REMISSION WITH CERTOLIZUMAB PEGOL CROHN'S DISEASE PATIENTS: A MULTI-CENTER EXPERIENCE OF COMPASSIONATE USE
    Danese, S.
    Mocciaro, F.
    Guidi, L.
    Scribano, M. L.
    Comberlato, M.
    Vangeli, M.
    Stefanelli, T.
    Pulitano, R.
    Manca, A.
    Armuzzi, A.
    Malesci, A.
    Prantera, C.
    Cottone, M.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 : S69 - S69
  • [28] Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2
    Feagan, B.
    Keininger, D.
    Coteur, G.
    Schreiber, S.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 661 - 662
  • [29] Regain of Response and Remission by Dose Adjustment in Patients with Crohn's Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study
    Sandborn, William
    D'Haens, Geert
    Vermeire, Severine
    Colombel, Jean-Frederick
    Fedorak, Richard
    Spehlmann, Martina
    Wolf, Douglas
    Mitchev, Krassimir
    Jamoul, Corinne
    Abreu, Maria
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S450 - S451
  • [30] Disease Location as a Risk Determinant for Maintenance of Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of Analyses From the PRECiSE 3 Study
    Schreiber, Stefan
    Randall, Charles
    Dubinsky, Marla
    Kosutic, Gordana
    Pierre-Louis, Bosny
    Spearman, Marshall
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S513 - S513
12345